Lowenstein client Reviva Pharmaceuticals, Inc. (Reviva), a Delaware corporation and a California-based, clinical-stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases, and Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (NASDAQ: TZAC), have entered into a definitive agreement and plan of merger for a business combination transaction resulting in a total post-money equity value of the combined company of approximately $119 million.
Reviva's primary focus is developing its lead product candidate, RP5063 (brilaroxazine), for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. RP5063 is a serotonin, dopamine, and nicotinic receptor active compound that has successfully completed a global Phase 2 clinical trial and has shown clinical efficacy and safety for schizophrenia and schizoaffective disorder.
The Lowenstein deal team included Steven M. Skolnick, Alan Wovsaniker, Valeska Pederson Hintz, Robert Bee, Tracy F. Buffer, Eugene R. Cheval, Timothy N. MacKay, Erica Perlmutter, and Madeline Roe.
